{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"End of induction-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"End of therapy-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"6-months off therapy-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"12-months off therapy-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"24-months off therapy-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"36-months off therapy-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"48-months off therapy-number with endocrinopathy"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"60-months off therapy-number with endocrinopathy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Endocrine screening and growth hormone (GH) testing were done in consenting intermediate risk patients at the end of induction therapy, the end of all therapy, and at 6, 12, 24, 36, 48, and 60 months off therapy. Endocrinopathy was defined as the presence of central hypothyroidism (free T4 concentration below normal with low or normal TSH concentration), growth hormone deficiency (peak growth hormone concentration below 5 ng/mL on dynamic testing), or ACTH deficiency (cortisol concentration below 14 ug/dL after low dose cosyntropin stimulation). Numbers of participants with endocrinopathy at each time point are reported. Please note the small numbers of participants with available data.","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"NUMBER","populationDescription":"Endocrine screening and growth hormone (GH) testing were done in consenting intermediate risk patients.","reportingStatus":"POSTED","timeFrame":"End of induction therapy (approximately 16 weeks from start of treatment), end of therapy (approximately 48 weeks from start of treatment), and 6, 12, 24, 36, 48, and 60 months off therapy","title":"Number of Participants With Endocrinopathy","type":"SECONDARY","unitOfMeasure":"participants"}